Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15489) 15489
Publication (1183) 1183
Book Chapter (81) 81
Book Review (44) 44
Conference Proceeding (40) 40
Dissertation (28) 28
Magazine Article (23) 23
Book / eBook (9) 9
Newspaper Article (5) 5
Data Set (4) 4
Web Resource (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6721) 6721
index medicus (4765) 4765
pyrazines - pharmacology (4534) 4534
animals (4072) 4072
male (3933) 3933
bortezomib (3907) 3907
pyrazines - therapeutic use (3000) 3000
female (2915) 2915
middle aged (2034) 2034
pyrazines - administration & dosage (2000) 2000
pyrazine (1819) 1819
oncology (1765) 1765
pyrazines (1746) 1746
aged (1562) 1562
adult (1539) 1539
boronic acids - therapeutic use (1530) 1530
rats (1520) 1520
boronic acids - pharmacology (1480) 1480
multiple myeloma - drug therapy (1475) 1475
mice (1447) 1447
pyrazines - chemistry (1355) 1355
boronic acids - administration & dosage (1239) 1239
pharmacology & pharmacy (1184) 1184
pyrazine derivatives (1177) 1177
hematology (1162) 1162
cell line, tumor (1071) 1071
pyrazines - adverse effects (1071) 1071
antineoplastic agents - therapeutic use (1000) 1000
antineoplastic agents - pharmacology (995) 995
treatment outcome (994) 994
apoptosis (973) 973
multiple myeloma (924) 924
chemistry, organic (915) 915
apoptosis - drug effects (905) 905
cancer (888) 888
antineoplastic combined chemotherapy protocols - therapeutic use (880) 880
analysis (843) 843
dose-response relationship, drug (829) 829
biochemistry & molecular biology (812) 812
chemistry, multidisciplinary (807) 807
sitagliptin phosphate (778) 778
proteasome inhibitors (712) 712
chemistry (708) 708
pyrazines - chemical synthesis (707) 707
chemistry, medicinal (697) 697
research (687) 687
chemistry, inorganic & nuclear (684) 684
boronic acids - adverse effects (676) 676
derivatives (610) 610
molecular structure (560) 560
therapy (557) 557
structure-activity relationship (555) 555
rats, sprague-dawley (553) 553
diabetes mellitus, type 2 - drug therapy (540) 540
expression (539) 539
multiple-myeloma (537) 537
time factors (523) 523
chemistry, physical (516) 516
care and treatment (513) 513
article (509) 509
ligands (504) 504
drug therapy, combination (468) 468
pyrazines - metabolism (468) 468
protease inhibitors - pharmacology (465) 465
activation (461) 461
triazoles - therapeutic use (458) 458
cell proliferation - drug effects (456) 456
chemotherapy (456) 456
multiple myeloma - pathology (454) 454
aged, 80 and over (453) 453
protease inhibitors - therapeutic use (447) 447
dexamethasone - administration & dosage (443) 443
endocrinology & metabolism (433) 433
drug synergism (421) 421
nf-kappa-b (411) 411
in vitro techniques (407) 407
thalidomide - analogs & derivatives (407) 407
pyrazines - pharmacokinetics (403) 403
antineoplastic agents - adverse effects (400) 400
cells (397) 397
clinical trials as topic (391) 391
complexes (390) 390
food science & technology (387) 387
dexamethasone (374) 374
proteins (368) 368
hypoglycemic agents - therapeutic use (367) 367
drug therapy (365) 365
cell biology (359) 359
proteasome endopeptidase complex - metabolism (359) 359
antineoplastic agents - administration & dosage (352) 352
thalidomide - administration & dosage (348) 348
pyridine (347) 347
kinetics (338) 338
models, molecular (336) 336
abridged index medicus (332) 332
cells, cultured (331) 331
disease models, animal (328) 328
medicine & public health (328) 328
sitagliptin (328) 328
spectroscopy (325) 325
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14241) 14241
Chinese (505) 505
Japanese (174) 174
German (165) 165
French (156) 156
Italian (147) 147
Russian (60) 60
Polish (48) 48
Spanish (47) 47
Czech (27) 27
Hungarian (15) 15
Dutch (10) 10
Portuguese (10) 10
Danish (7) 7
Swedish (7) 7
Slovak (5) 5
Korean (4) 4
Norwegian (4) 4
Hebrew (3) 3
Finnish (2) 2
Romanian (2) 2
Turkish (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. The pyrazines
: Supplement I
by Brown, D. J
2002, The chemistry of heterocyclic compounds, ISBN 0471403822, Volume 58
Pyrazines
Web Resource
Details down arrow
2. Full Text Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study
by Rosiñol, Laura and Oriol, Albert and Teruel, Ana Isabel and Hernández, Dolores and López-Jiménez, Javier and De La Rubia, Javier and Granell, Miquel and Besalduch, Joan and Palomera, Luis and González, Yolanda and Etxebeste, Ma. Asunción and Díaz-Mediavilla, Joaquín and Hernández, Miguel T and De Arriba, Felipe and Gutiérrez, Norma C and Martín-Ramos, Ma. Luisa and Cibeira, Ma. Teresa and Mateos, Ma. Victoria and Martínez, Joaquín and Alegre, Adrián and Lahuerta, Juan José and San Miguel, Jesús and Bladé, Joan and Programa Estudio & Terapeutica Hem and Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
TRIAL | PLUS DEXAMETHASONE | ABNORMALITIES | HIGH-DOSE THERAPY | COMPLETE RESPONSE | DOXORUBICIN | PERIPHERAL NEUROPATHY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | DELETION | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
by Green, Jennifer B and Bethel, M. Angelyn and Armstrong, Paul W and Buse, John B and Engel, Samuel S and Garg, Jyotsna and Josse, Robert and Kaufman, Keith D and Koglin, Joerg and Korn, Scott and Lachin, John M and McGuire, Darren K and Pencina, Michael J and Standl, Eberhard and Stein, Peter P and Suryawanshi, Shailaja and Van de Werf, Frans and Peterson, Eric D and Holman, Rury R and TECOS Study Grp and TECOS Study Group
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 232 - 242
The addition of sitagliptin to usual care in patients with type 2 diabetes and cardiovascular disease was not associated with any change in the risk of major... 
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | GLUCOSE-LOWERING DRUGS | STRATEGIES | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - therapeutic use | Triazoles - adverse effects | Double-Blind Method | Follow-Up Studies | Administration, Oral | Humans | Kaplan-Meier Estimate | Hospitalization - statistics & numerical data | Pyrazines - therapeutic use | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - blood | Heart Diseases - etiology | Heart Diseases - epidemiology | Pyrazines - adverse effects | Cardiovascular Diseases - mortality | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Heart Failure - etiology | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Triazoles - therapeutic use | Type 2 diabetes | Care and treatment | Usage | Clinical trials | Influence | Sitagliptin | Dosage and administration | Cardiovascular diseases | Myocardial infarction | Cerebral infarction | Stroke | Inhibitor drugs | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Side effects | Pancreatic cancer | Hemoglobin | Diabetes | Health risk assessment | Drug therapy | Diabetes mellitus (non-insulin dependent) | Heart diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: Design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines
by Huang, Boshi and Liang, Xin and Li, Xiao and Li, Cuicui and Chen, Wenmin and Liu, Xinyong and Liu, Tao and Liu, Huiqing and Sun, Yueyue and Fu, Lu and De Clercq, Erik and Pannecouque, Christophe and Zhan, Peng
European Journal of Medicinal Chemistry, ISSN 0223-5234, 03/2015, Volume 93, pp. 330 - 337
Through a structure-guided core-refining approach, a series of novel imidazo[1,2- ]pyrazine derivatives were designed, synthesized and evaluated as HIV-1... 
Molecular simulation | HIV-1 RT | Biological activity | Imidazo[1,2-a]pyrazines | Core-refining | NNRTIs | CHEMISTRY, MEDICINAL | COLORIMETRIC ASSAY | REVERSE-TRANSCRIPTASE | DISCOVERY | STRATEGIES | INHIBITORS | CORE-REFINING APPROACH | DERIVATIVES | Anti-HIV Agents - pharmacology | Chemistry Techniques, Synthetic | HIV-1 - drug effects | HIV Reverse Transcriptase - antagonists & inhibitors | Computational Biology | Imidazoles - chemistry | Reverse Transcriptase Inhibitors - pharmacology | Pyrazines - metabolism | Structure-Activity Relationship | Anti-HIV Agents - chemical synthesis | Pyrazines - chemical synthesis | Reverse Transcriptase Inhibitors - chemistry | Reverse Transcriptase Inhibitors - chemical synthesis | HIV Reverse Transcriptase - metabolism | Pyrazines - chemistry | Anti-HIV Agents - chemistry | Drug Design | HIV-1 - enzymology | Protein Conformation | Molecular Docking Simulation | Reverse Transcriptase Inhibitors - metabolism | Anti-HIV Agents - metabolism | Pyrazines - pharmacology | HIV Reverse Transcriptase - chemistry | HIV (Viruses) | Antiviral agents | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Selexipag for the Treatment of Pulmonary Arterial Hypertension
by Sitbon, Olivier and Channick, Richard and Chin, Kelly M and Frey, Aline and Gaine, Sean and Galiè, Nazzareno and Ghofrani, Hossein-Ardeschir and Hoeper, Marius M and Lang, Irene M and Preiss, Ralph and Rubin, Lewis J and Di Scala, Lilla and Tapson, Victor and Adzerikho, Igor and Liu, Jinming and Moiseeva, Olga and Zeng, Xiaofeng and Simonneau, Gérald and McLaughlin, Vallerie V and GRIPHON Investigators
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 26, pp. 2522 - 2533
Among over 1100 patients with pulmonary arterial hypertension who received selexipag, an oral selective IP prostacyclin-receptor agonist, or placebo, the risk... 
SURVIVAL | 5 INHIBITOR THERAPY | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | ANTAGONIST | PROSTACYCLIN RECEPTOR AGONIST | TIME | ORAL TREPROSTINIL | Hypertension, Pulmonary - mortality | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Kaplan-Meier Estimate | Hospitalization - statistics & numerical data | Male | Pyrazines - therapeutic use | Disease Progression | Prodrugs - adverse effects | Acetamides - therapeutic use | Pyrazines - adverse effects | Acetamides - adverse effects | Female | Aged | Hypertension, Pulmonary - drug therapy | Prodrugs - therapeutic use | Hypertension, Pulmonary - complications | Clinical trials | Usage | Drug therapy | Pulmonary hypertension | Hypertension | Headache | Jaw | Endothelin | Pulmonary arteries | Diarrhea | Nausea | Prostacyclin | Patients | Pain | Circulatory system | Phosphodiesterase | Fees & charges | Substance abuse treatment | Statistical analysis | Committees | Drug dosages | Pharmaceuticals | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Synthesis of 1-functionalized imidazo[1,5-а]pyrazolo[5,1-с]pyrazines
by Tsizorik, Nazar M and Hrynyshyn, Yevhenii V and Bol’but, Andriy V and Vovk, Mykhailo V
Chemistry of Heterocyclic Compounds, ISSN 0009-3122, 11/2018, Volume 54, Issue 11, pp. 1075 - 1078
4-Chloropyrazolo[1,5-a]pyrazines react with ethyl isocyanoacetate to form ethyl imidazo[1,5-a]pyrazolo[5,1-c]pyrazine-1-carboxylates, hydrolysis of which... 
functional derivatives | Chemistry | Pharmacy | 4-chloropyrazolo[1,5- a ]pyrazines | ethyl isocyanoacetate | imidazo[1,5- a ]pyrazolo[5,1- с ]pyrazines | Organic Chemistry | imidazo[1,5-a]pyrazolo[5,1-с]pyrazines | 4-chloropyrazolo[1,5-a]pyrazines | SERIES | SAR | HIGH-AFFINITY | CHEMISTRY, ORGANIC | imidazo[1,5-a] pyrazolo[5,1-c]pyrazines | DISCOVERY | UREAS | POTENT | PARTIAL AGONIST | INHIBITORS | AMIDES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
by Plosker, Greg L
Drugs, ISSN 0012-6667, 2/2014, Volume 74, Issue 2, pp. 223 - 242
Sitagliptin (Januvia®, Xelevia™, Glactiv®, Tesavel®) is an orally administered, potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | DRUG-NAIVE PATIENTS | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | COST-EFFECTIVENESS | ONGOING METFORMIN THERAPY | INITIAL COMBINATION THERAPY | IMPROVES GLYCEMIC CONTROL | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | FIXED-DOSE COMBINATION | TOXICOLOGY | JAPANESE PATIENTS | RENAL-INSUFFICIENCY | Triazoles - administration & dosage | Triazoles - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Pyrazines - administration & dosage | Pyrazines - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Triazoles - pharmacology | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Triazoles - pharmacokinetics | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Pyrazines - pharmacology | Drug Combinations | Triazoles - therapeutic use | Type 2 diabetes | Sitagliptin | Usage | Care and treatment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
by Garcia Fortanet, Jorge and Chen, Christine Hiu-Tung and Chen, Ying-Nan P and Chen, Zhouliang and Deng, Zhan and Firestone, Brant and Fekkes, Peter and Fodor, Michelle and Fortin, Pascal D and Fridrich, Cary and Grunenfelder, Denise and Ho, Samuel and Kang, Zhao B and Karki, Rajesh and Kato, Mitsunori and Keen, Nick and Labonte, Laura R and Larrow, Jay and Lenoir, Francois and Liu, Gang and Liu, Shumei and Lombardo, Franco and Majumdar, Dyuti and Meyer, Matthew J and Palermo, Mark and Perez, Lawrence and Pu, Minying and Ramsey, Timothy and Sellers, William R and Shultz, Michael D and Stams, Travis and Towler, Christopher and Wang, Ping and Williams, Sarah L and Zhang, Ji-Hu and Lamarche, Matthew J and Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Journal of Medicinal Chemistry, ISSN 0022-2623, 09/2016, Volume 59, Issue 17, pp. 7773 - 7782
SHP2 is a nonreceptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene involved in cell growth and differentiation via the MAPK signaling pathway.... 
DESIGN | CHEMISTRY, MEDICINAL | PROTEIN-TYROSINE PHOSPHATASES | PTPN11 | ACUTE MYELOID-LEUKEMIA | MUTATIONS | CANCER | Neoplasm Transplantation | Pyrimidines - chemical synthesis | Allosteric Regulation | Antineoplastic Agents - chemical synthesis | Humans | Crystallography, X-Ray | Male | Structure-Activity Relationship | Pyrimidines - chemistry | Heterografts | Piperidines - pharmacology | Drug Design | Female | Piperidines - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Piperidines - chemistry | Administration, Oral | Mice, Inbred C57BL | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - antagonists & inhibitors | Models, Molecular | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - chemistry | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Piperidines - chemical synthesis | Pyrazines - chemical synthesis | Pyrazines - chemistry | Animals | High-Throughput Screening Assays | Mice, Nude | Pyrazines - pharmacokinetics | Allosteric Site | Cell Line, Tumor | Pyrimidines - pharmacokinetics | Protein Conformation | Pyrazines - pharmacology | 60 APPLIED LIFE SCIENCES | INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
by Byrd, John C and Harrington, Bonnie and O’Brien, Susan and Jones, Jeffrey A and Schuh, Anna and Devereux, Steve and Chaves, Jorge and Wierda, William G and Awan, Farrukh T and Brown, Jennifer R and Hillmen, Peter and Stephens, Deborah M and Ghia, Paolo and Barrientos, Jacqueline C and Pagel, John M and Woyach, Jennifer and Johnson, Dave and Johnson, Amy J and Huang, Jane and Wang, Xiaolin and Kaptein, Allard and Lannutti, Brian J and Covey, Todd and Fardis, Maria and McGreivy, Jesse and Hamdy, Ahmed and Rothbaum, Wayne and Izumi, Raquel and Diacovo, Thomas G and Furman, Richard R
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights